Tonix Pharmaceuticals Holding Corp. Income Statement
TNXP|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$10M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$137M
FY2025
Net Income
-$130M
FY2025
Tonix Pharmaceuticals Holding Corp. reported $10M in revenue and $130M in net loss for FY2025. Revenue has grown at a 14.0% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $10.1M | $7.8M | $7.8M |
| Cost of Revenue | $7.8M | $4.7M | $4.7M |
| SG&A Expense | $40.1M | $34.8M | $30.2M |
| R&D Expense | $40.0M | $86.7M | $81.9M |
| Operating Income | -$136.7M | -$118.4M | -$112.1M |
| Net Income | -$130.0M | -$116.7M | -$110.2M |
| EPS (Basic) | -$176.60 | -$14720.25 | -$20.01 |
| EPS (Diluted) | -$176.60 | -$14720.25 | -$20.01 |
| Shares Outstanding | 4.4M | 20.9K | 12.4M |
| Operating Margin | -1354.3% | -1523.9% | -1443.0% |
| Profit Margin | -1288.3% | -1501.8% | -1418.9% |